查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2018824

胰島素輸注裝置市場：按給藥方式、胰島素類型、分銷管道、最終用戶、應用和年齡層分類－2026-2032年全球市場預測

Insulin Delivery Devices Market by Delivery Method, Insulin Type, Distribution Channel, End User, Application, Age Group - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，胰島素輸送設備市場價值將達到 338.6 億美元，到 2026 年將成長至 364.5 億美元，到 2032 年將達到 586.3 億美元，複合年成長率為 8.15%。

主要市場統計數據
基準年 2025 338.6億美元
預計年份：2026年 364.5億美元
預測年份 2032 586.3億美元
複合年成長率 (%) 8.15%

透過最尖端科技、以患者為中心的使用者體驗和綜合治療方案，胰島素輸送裝置不斷發展演進。

在技​​術飛躍和以患者為中心的護理理念日益受到重視的推動下，胰島素給藥領域經歷了翻天覆地的變化。近年來，創新使胰島素筆從簡單的機械裝置發展成為整合數位化監測功能的複雜平台。同時，傳統注射器的精確度和設計也得到了改進，從而減輕了患者的不適感。另一方面，胰島素幫浦也從有線系統發展成為無線穿戴式技術，提供即時數據連接和封閉回路型控制，將慢性病管理轉變為無縫且個人化的體驗。

數位化、互聯互通和個人化治療方法正在改變胰島素輸送技術。

在胰島素治療領域，數位化和互聯互通正與先進的治療模式融合，帶來翻天覆地的改變。新興的封閉回路型系統利用人工智慧技術，根據持續血糖監測動態調整胰島素劑量，從而提高患者的自主性，並減輕人工干預的負擔。同時，行動醫療應用的普及實現了無縫遠端監測，使臨床醫生能夠以前所未有的精細程度調整治療方案，並在出現異常情況時主動干預。

評估美國新關稅政策對胰島素輸送裝置供應鏈和成本結構的廣泛影響。

美國在2025年實施的新關稅措施對胰島素輸注設備的供應鏈產生了多方面的影響。隨著關鍵零件進口關稅的提高，製造商面臨原料成本飆升的困境，而這又波及到契約製造協議和分銷商的定價結構中。為此，許多設備製造商正在重新審視其全球籌資策略，並考慮將關鍵組裝工序外包至近岸地區，以降低國際貿易政策波動的風險。

本研究闡明了按給藥方法、胰島素類型、分銷管道、最終用戶、應用和年齡層分類的關鍵市場細分趨勢。

對市場細分的詳細分析揭示了胰島素給藥生態系統中存在的各種需求和成長方向。按給藥方式分類，產品範圍涵蓋了從注重劑量精準和隱蔽性的易用型胰島素筆，到具備無線連接的先進胰島素泵，甚至還包括滿足患者偏好和注射舒適度的傳統胰島素注射器和新型噴射注射器。每種給藥方式都針對獨特的用藥依從性挑戰和臨床需求。

揭示美洲、歐洲、中東和非洲以及亞太市場的區域成長模式和戰略機會。

區域市場趨勢凸顯了主要地理區域面臨的不同策略挑戰。在美洲，完善的醫療基礎設施和報銷體系推動了閉合迴路系統和數位健康整合的快速普及，而集中投入的研發資金則持續推動著設備不斷改進。同時，支付模式的轉變和基於價值的醫療試點計畫正在影響採購決策，並加速性價比評估。

分析推動胰島素輸注設備市場競爭優勢的關鍵創新者和策略夥伴關係。

醫療設備的競爭格局由老牌領導企業和敏捷的技術顛覆者共同塑造。老牌製造商正利用其在胰島素給藥領域數十年的專業經驗，推出具有更強連接性和以用戶為中心的新一代胰島素筆和胰島素幫浦。同時，數位醫療Start-Ups正與製藥公司合作，將軟體驅動的演算法和基於雲端的分析技術整合到其給藥平台中。

為行業領導者提供實用見解和策略挑戰，以應對胰島素給藥方式的轉型並推動永續成長。

為了在快速變化的市場中取得成功，行業領導者必須優先將先進的分析和人工智慧技術整合到設備平台中，以實現即時決策支援和預測性干預。透過區域生產基地實現製造地多元化，可以有效規避貿易政策波動的影響，並提升供應鏈的彈性。此外，積極與保險公司和監管相關人員保持溝通至關重要，這有助於獲得有利的報銷途徑，並簡化設備核准流程。

嚴謹的多維調查方法為全面分析胰島素輸送裝置市場的市場動態提供了支持。

本分析基於嚴謹的研究框架，結合了質性和量性調查方法。主要數據透過對關鍵意見領袖（KOL）、醫療設備製造商和醫療保健專業人員的深度訪談收集，並輔以一系列專家訪談，以了解市場趨勢和市場接受度促進因素。次要研究包括監管文件、同行評審文獻和公開的技術文件，以確保對醫療設備規格和臨床性能的全面理解。

全面概述了創新、政策影響和市場趨勢如何共同塑造胰島素給藥裝置。

數位醫療、政策轉變以及患者不斷變化的需求正在加速胰島素輸注裝置的創新。隨著關稅重塑供應鏈和區域市場日益多元化，相關人員必須不斷調整策略，以保持競爭優勢並創造價值。細分市場分析凸顯了針對不同給藥方式、胰島素製劑、分銷管道、終端用戶、臨床應用和年齡層客製化產品和服務的重要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 胰島素輸注裝置市場：以輸注方式分類

  • 胰島素筆
  • 胰島素幫浦
  • 胰島素注射器
  • 噴射注射器

第9章：以胰島素類型分類的胰島素輸注裝置市場

  • 中間類型
  • 長效型
  • 預混合料
  • 快速起效

第10章：胰島素輸注裝置市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章 胰島素輸注設備市場：依最終用戶分類

  • 門診部
  • 診所
  • 居家醫療
  • 醫院

第12章 胰島素輸注裝置市場：依應用分類

  • 妊娠糖尿病
  • 1型糖尿病
  • 2型糖尿病

第13章：胰島素輸注裝置市場：依年齡層別分類

  • 成人版
  • 老年人
  • 兒童

第14章 胰島素輸注裝置市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 胰島素輸注裝置市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 胰島素輸注裝置市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國胰島素輸送裝置市場

第18章：中國胰島素輸注裝置市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Ascensia Diabetes Care Holdings AG
  • B. Braun SE
  • Biocon
  • Debiotech SA
  • Eli Lilly and Company
  • Embecta Corp.
  • Gerresheimer AG
  • ICU Medical, Inc.
  • Insulet Corporation
  • Jiangsu Delfu medical device Co.,Ltd
  • Johnson & Johnson Services, Inc.
  • MannKind Corporation
  • Medtronic PLC
  • Nipro Corporation
  • Novo Nordisk A/S
  • Owen Mumford Ltd.
  • Roche Diabetes Care, Inc.
  • Sanofi SA
  • Sequel Med Tech, LLC
  • SOOIL Developments Co., Ltd
  • Tandem Diabetes Care, Inc.
  • Terumo Corporation
  • Wockhardt Limited
  • Ypsomed AG
Product Code: MRR-ED54C46E8A4A

The Insulin Delivery Devices Market was valued at USD 33.86 billion in 2025 and is projected to grow to USD 36.45 billion in 2026, with a CAGR of 8.15%, reaching USD 58.63 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 33.86 billion
Estimated Year [2026] USD 36.45 billion
Forecast Year [2032] USD 58.63 billion
CAGR (%) 8.15%

Unveiling the Evolution of Insulin Delivery Devices with Cutting-Edge Technologies, Patient-Focused User Experiences, and Integrative Therapeutic Solutions

The landscape of insulin delivery has undergone a profound evolution, driven by technological breakthroughs and an intensified focus on patient-centric care. Over recent years, innovations have propelled insulin pens from simple mechanical devices into sophisticated platforms that integrate digital monitoring capabilities, while traditional syringes have seen design enhancements to improve precision and reduce patient discomfort. Meanwhile, insulin pumps have advanced from tethered systems into wireless, wearable technologies that offer real-time data connectivity and closed-loop control, transforming chronic disease management into a seamless, personalized experience.

This era of transformation has been further accelerated by an expanding clinical understanding of insulin pharmacodynamics and the pursuit of optimized glycemic control across diverse patient populations. As manufacturers and healthcare providers collaborate more closely, the integration of smart sensors, interoperable software ecosystems, and intuitive user interfaces is redefining expectations for safety, efficacy, and convenience. Consequently, stakeholders across the value chain must now navigate a dynamic environment where regulatory oversight, reimbursement frameworks, and patient advocacy intersect, shaping the strategic priorities of device developers and care delivery organizations alike.

Charting the Transformative Shifts in Insulin Delivery Technology Fueled by Digitalization, Connectivity, and Personalized Treatment Approaches

The insulin delivery arena is witnessing seismic shifts as digitalization and connectivity converge with advanced treatment paradigms. Emerging closed-loop systems are leveraging artificial intelligence to dynamically adjust dosage based on continuous glucose monitoring, elevating patient autonomy and reducing the burden of manual interventions. At the same time, the proliferation of mobile health applications has enabled seamless remote monitoring, empowering clinicians to tailor regimens with unprecedented granularity and to intervene proactively when deviations occur.

In parallel, there is a growing emphasis on modular device architectures that foster interoperability and future-proof investments. Developers are adopting open-platform standards to facilitate third-party integration of sensors, dosing algorithms, and telehealth services, creating an ecosystem where innovation can flourish through strategic partnerships. Moreover, multifunctional delivery devices are being designed to accommodate combination therapies and real-time biometric feedback, reflecting a holistic approach to diabetes management that transcends insulin alone. Together, these transformative shifts are setting new benchmarks for performance, patient adherence, and long-term clinical outcomes.

Assessing the Far-Reaching Ramifications of New United States Tariff Policies on Insulin Delivery Device Supply Chains and Cost Structures

The implementation of new tariff measures in the United States for 2025 is exerting a multifaceted impact on the insulin delivery device supply chain. As import duties on critical components rise, manufacturers are facing higher input costs that cascade through contract manufacturing agreements and distributor pricing structures. In response, many device producers are reevaluating their global sourcing strategies, considering nearshoring of key assembly operations to mitigate exposure to volatile international trade policies.

These shifts are not limited to raw materials alone; ancillary services such as calibration, software updates, and customer support are also subject to elevated expenses when conducted cross-border. Consequently, healthcare providers and payers are confronting pressure to absorb or negotiate additional costs, potentially affecting reimbursement negotiations and formulary placements. In anticipation of prolonged tariff regimes, industry participants are exploring vertical integration models, investing in domestic manufacturing capabilities, and forging strategic alliances to preserve supply chain resilience and maintain competitive pricing for end users.

Deciphering Key Market Segmentation Dynamics Across Delivery Methods, Insulin Types, Channels, End Users, Applications, and Age Groups

A nuanced understanding of market segmentation reveals the diverse needs and growth vectors within the insulin delivery ecosystem. When evaluating based on delivery method, offerings span from user-friendly insulin pens that emphasize dose accuracy and discretion to advanced insulin pumps equipped with wireless connectivity, alongside traditional insulin syringes and novel jet injectors that cater to patient preferences and injection comfort. Each modality addresses distinct adherence challenges and clinical requirements.

With respect to insulin type, distinctions emerge between intermediate-acting formulations prized for basal control, long-acting analogues designed for stable plasma profiles, pre-mixed preparations offering combination dosing, and rapid-acting variants engineered for postprandial glycemic spikes. These therapeutic classes influence device compatibility, dosing algorithms, and patient education strategies.

Distribution channels further differentiate market dynamics, encompassing hospital pharmacies that support acute and inpatient care, online pharmacies providing convenience and home delivery, and retail pharmacies serving outpatient populations. The interplay among these channels shapes procurement practices and patient access.

End users range from ambulatory care centers and specialty clinics to homecare settings and hospitals, each with specific device requirements, training needs, and service models. Application segments include gestational diabetes management protocols, intensive insulin regimens for type 1 diabetes, and adjustable dosing schedules for type 2 diabetes, reflecting varied clinical pathways. Finally, age group considerations-adult, geriatric, and pediatric-underscore the importance of ergonomic design, dosage precision, and user interfaces tailored to cognitive and dexterity capabilities across the lifespan.

Unearthing Regional Growth Patterns and Strategic Opportunities Across Americas, Europe Middle East Africa, and Asia Pacific Markets

Regional market behavior highlights distinct strategic imperatives across major geographic zones. In the Americas, robust healthcare infrastructure and reimbursement frameworks have driven rapid adoption of closed-loop systems and digital health integration, while concentrated R&D investments continue to spur incremental device enhancements. Meanwhile, shifting payer models and value-based care pilots are influencing procurement decisions and accelerating price-performance evaluations.

Within Europe, the Middle East, and Africa, regulatory harmonization efforts and cross-border trade agreements are shaping market entry strategies. Mature Western European markets emphasize clinical evidence and health technology assessments, whereas emerging markets in the Middle East and Africa present opportunities for cost-effective device variants and public-private partnerships to expand diabetes care access. Variability in reimbursement policies and economic heterogeneity necessitates tailored market approaches.

In Asia-Pacific, rising diabetes prevalence and expanding healthcare access are fueling demand for both basic and advanced delivery solutions. Nations with well-established healthcare systems are increasingly receptive to telemedicine-enabled pumps, while developing economies prioritize affordability and distribution network reach. Local manufacturing initiatives and government programs aimed at reducing out-of-pocket expenditure are further influencing competitive dynamics and innovation priorities.

Profiling Major Innovators and Strategic Partnerships Driving Competitive Advantage in the Insulin Delivery Device Landscape

The competitive landscape is defined by established medical device leaders and agile technology disruptors. Legacy manufacturers are leveraging decades of insulin delivery expertise to introduce next-generation pens and pumps with enhanced connectivity and user-centric features. Simultaneously, digital health startups are forging alliances with pharmaceutical companies to integrate software-driven algorithms and cloud-based analytics into delivery platforms.

Strategic partnerships between device producers and glucose monitoring innovators are yielding closed-loop ecosystems, while collaborations with telehealth providers are extending remote patient support capabilities. Investment in intellectual property around sensor miniaturization and secure data transmission is intensifying, as firms seek to protect differentiated offerings. Moreover, mergers and acquisitions are consolidating expertise across hardware, software, and service domains, shaping the competitive hierarchy and setting the stage for disruptive new entrants.

Actionable Insights and Strategic Imperatives for Industry Leaders to Navigate Disruption and Drive Sustainable Growth in Insulin Delivery

To thrive in a rapidly evolving market, industry leaders should prioritize the integration of advanced analytics and artificial intelligence into device platforms, enabling real-time decision support and predictive intervention. Diversification of manufacturing footprints through regional production hubs can safeguard against trade policy fluctuations and enhance supply chain agility. Additionally, proactive engagement with payer and regulatory stakeholders is essential to secure favorable reimbursement pathways and streamline device approvals.

Investing in patient education programs and digital literacy initiatives will bolster device adherence and foster brand loyalty. Collaborative research partnerships with academic and clinical institutions can accelerate the validation of novel delivery technologies, while strategic alliances with telemedicine providers can enhance post-market support services. Finally, exploring tailored solutions for underserved demographics and emerging markets will unlock new growth opportunities and reinforce corporate social responsibility commitments.

Rigorous Multidimensional Research Methodology Underpinning Comprehensive Analysis of Insulin Delivery Device Market Dynamics

This analysis was underpinned by a rigorous research framework combining qualitative and quantitative methodologies. Primary data was collected through in-depth interviews with key opinion leaders, device manufacturers, and healthcare providers, supplemented by a series of expert surveys to capture market sentiment and adoption drivers. Secondary research encompassed regulatory filings, peer-reviewed literature, and publicly available technical documentation, ensuring a comprehensive understanding of device specifications and clinical performance.

Data triangulation techniques were employed to validate findings across multiple sources, while trend extrapolation methods illuminated emerging patterns without relying on speculative forecasting. Validation workshops with multidisciplinary stakeholders provided a forum to refine insights and confirm strategic implications. This robust methodology ensures that the conclusions drawn reflect both the current state of the insulin delivery device market and the technological, regulatory, and economic forces shaping its trajectory.

Concluding Perspectives on the Intersection of Innovation, Policy Impact, and Market Trends Shaping the Future of Insulin Delivery

Innovation in insulin delivery devices is accelerating, shaped by the convergence of digital health, policy shifts, and evolving patient expectations. As tariffs reshape supply chains and regional markets diversify, stakeholders must continuously adapt their strategies to maintain competitive advantage and deliver value. Segmentation analysis underscores the importance of customizing offerings across delivery methods, insulin formulations, distribution channels, end users, clinical applications, and age demographics.

By aligning product development with regional healthcare imperatives and forging strategic partnerships across the digital ecosystem, manufacturers and care providers can optimize outcomes and expand access. The insights presented in this summary lay the groundwork for informed decision making, guiding investments in technology, manufacturing, and market entry to meet the demands of a dynamic insulin delivery landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Insulin Delivery Devices Market, by Delivery Method

  • 8.1. Insulin Pens
  • 8.2. Insulin Pumps
  • 8.3. Insulin Syringes
  • 8.4. Jet Injectors

9. Insulin Delivery Devices Market, by Insulin Type

  • 9.1. Intermediate-Acting
  • 9.2. Long-Acting
  • 9.3. Pre-Mixed
  • 9.4. Rapid-Acting

10. Insulin Delivery Devices Market, by Distribution Channel

  • 10.1. Hospital Pharmacies
  • 10.2. Online Pharmacies
  • 10.3. Retail Pharmacies

11. Insulin Delivery Devices Market, by End User

  • 11.1. Ambulatory Care Centers
  • 11.2. Clinics
  • 11.3. Homecare Settings
  • 11.4. Hospitals

12. Insulin Delivery Devices Market, by Application

  • 12.1. Gestational Diabetes
  • 12.2. Type 1 Diabetes
  • 12.3. Type 2 Diabetes

13. Insulin Delivery Devices Market, by Age Group

  • 13.1. Adult
  • 13.2. Geriatric
  • 13.3. Pediatric

14. Insulin Delivery Devices Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Insulin Delivery Devices Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Insulin Delivery Devices Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Insulin Delivery Devices Market

18. China Insulin Delivery Devices Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abbott Laboratories
  • 19.6. Ascensia Diabetes Care Holdings AG
  • 19.7. B. Braun SE
  • 19.8. Biocon
  • 19.9. Debiotech SA
  • 19.10. Eli Lilly and Company
  • 19.11. Embecta Corp.
  • 19.12. Gerresheimer AG
  • 19.13. ICU Medical, Inc.
  • 19.14. Insulet Corporation
  • 19.15. Jiangsu Delfu medical device Co.,Ltd
  • 19.16. Johnson & Johnson Services, Inc.
  • 19.17. MannKind Corporation
  • 19.18. Medtronic PLC
  • 19.19. Nipro Corporation
  • 19.20. Novo Nordisk A/S
  • 19.21. Owen Mumford Ltd.
  • 19.22. Roche Diabetes Care, Inc.
  • 19.23. Sanofi S.A.
  • 19.24. Sequel Med Tech, LLC
  • 19.25. SOOIL Developments Co., Ltd
  • 19.26. Tandem Diabetes Care, Inc.
  • 19.27. Terumo Corporation
  • 19.28. Wockhardt Limited
  • 19.29. Ypsomed AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INSULIN DELIVERY DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL INSULIN DELIVERY DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY DELIVERY METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY INSULIN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES INSULIN DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA INSULIN DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY INSULIN PENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY INSULIN PENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY INSULIN PENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY INSULIN PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY INSULIN PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY INSULIN PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY INSULIN SYRINGES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY INSULIN SYRINGES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY INSULIN SYRINGES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY JET INJECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY JET INJECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY JET INJECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY INTERMEDIATE-ACTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY INTERMEDIATE-ACTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY INTERMEDIATE-ACTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY LONG-ACTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY LONG-ACTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY LONG-ACTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY PRE-MIXED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY PRE-MIXED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY PRE-MIXED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY RAPID-ACTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY RAPID-ACTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY RAPID-ACTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY GESTATIONAL DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY GESTATIONAL DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY GESTATIONAL DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY TYPE 1 DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY TYPE 1 DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY TYPE 2 DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY TYPE 2 DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS INSULIN DELIVERY DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS INSULIN DELIVERY DEVICES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS INSULIN DELIVERY DEVICES MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS INSULIN DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS INSULIN DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS INSULIN DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS INSULIN DELIVERY DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA INSULIN DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA INSULIN DELIVERY DEVICES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA INSULIN DELIVERY DEVICES MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA INSULIN DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA INSULIN DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA INSULIN DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA INSULIN DELIVERY DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA INSULIN DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA INSULIN DELIVERY DEVICES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA INSULIN DELIVERY DEVICES MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA INSULIN DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA INSULIN DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA INSULIN DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA INSULIN DELIVERY DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA INSULIN DELIVERY DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA INSULIN DELIVERY DEVICES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA INSULIN DELIVERY DEVICES MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA INSULIN DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA INSULIN DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA INSULIN DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA INSULIN DELIVERY DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE INSULIN DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE INSULIN DELIVERY DEVICES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE INSULIN DELIVERY DEVICES MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE INSULIN DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE INSULIN DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE INSULIN DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE INSULIN DELIVERY DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST INSULIN DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST INSULIN DELIVERY DEVICES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST INSULIN DELIVERY DEVICES MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST INSULIN DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST INSULIN DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST INSULIN DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST INSULIN DELIVERY DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA INSULIN DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA INSULIN DELIVERY DEVICES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA INSULIN DELIVERY DEVICES MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA INSULIN DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA INSULIN DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA INSULIN DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA INSULIN DELIVERY DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC INSULIN DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC INSULIN DELIVERY DEVICES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC INSULIN DELIVERY DEVICES MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC INSULIN DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC INSULIN DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC INSULIN DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC INSULIN DELIVERY DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN INSULIN DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN INSULIN DELIVERY DEVICES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN INSULIN DELIVERY DEVICES MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN INSULIN DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN INSULIN DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN INSULIN DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN INSULIN DELIVERY DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GCC INSULIN DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GCC INSULIN DELIVERY DEVICES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 138. GCC INSULIN DELIVERY DEVICES MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. GCC INSULIN DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. GCC INSULIN DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. GCC INSULIN DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. GCC INSULIN DELIVERY DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION INSULIN DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION INSULIN DELIVERY DEVICES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION INSULIN DELIVERY DEVICES MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION INSULIN DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION INSULIN DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION INSULIN DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION INSULIN DELIVERY DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS INSULIN DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS INSULIN DELIVERY DEVICES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS INSULIN DELIVERY DEVICES MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS INSULIN DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS INSULIN DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS INSULIN DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS INSULIN DELIVERY DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. G7 INSULIN DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. G7 INSULIN DELIVERY DEVICES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 159. G7 INSULIN DELIVERY DEVICES MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. G7 INSULIN DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. G7 INSULIN DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. G7 INSULIN DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 163. G7 INSULIN DELIVERY DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. NATO INSULIN DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. NATO INSULIN DELIVERY DEVICES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 166. NATO INSULIN DELIVERY DEVICES MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. NATO INSULIN DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 168. NATO INSULIN DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. NATO INSULIN DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. NATO INSULIN DELIVERY DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL INSULIN DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES INSULIN DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED STATES INSULIN DELIVERY DEVICES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED STATES INSULIN DELIVERY DEVICES MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES INSULIN DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES INSULIN DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED STATES INSULIN DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES INSULIN DELIVERY DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA INSULIN DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 180. CHINA INSULIN DELIVERY DEVICES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 181. CHINA INSULIN DELIVERY DEVICES MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. CHINA INSULIN DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. CHINA INSULIN DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. CHINA INSULIN DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. CHINA INSULIN DELIVERY DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)